Lactobacillus LA85 and LRa05
WHAT ARE LACTIC ACID BACTERIA?
Lactobacillus acidophilus and Lactobacillus rhamnosus are among the most widely studied probiotic bacterial strains. They are natural inhabitants of the human intestine and part of the physiological intestinal flora. These lactic acid bacteria produce lactic acid as part of their metabolism. Both strains are acid- and bile-tolerant, which allows them to survive passage through the stomach. L. acidophilus prefers to colonize the small intestine, while L. rhamnosus can be found in both the small and large intestines. In combination with prebiotic fibers such as inulin, which serves as a nutrient source for these bacteria, they form a synbiotic system.
WHY LACTIC ACID BACTERIA?
The two Lactobacillus strains are the subject of extensive scientific research. L. acidophilus produces the enzyme lactase, which plays a role in the breakdown of milk sugar. L. rhamnosus has the ability to adhere to intestinal wall cells. Both strains can produce antimicrobial substances and interact with immune cells in the intestinal mucosa. The combination with inulin is being investigated in research, as the prebiotic can be used as a nutrient source by certain groups of bacteria, in particular Bifidobacterium and Lactobacillus species. These bacteria contribute to the production of short-chain fatty acids, which are produced in the large intestine.
The combination of L. acidophilus, L. rhamnosus, and inulin has been the subject of numerous human studies. Research studies with approximately 10 billion CFU per strain and 3 g of inulin daily have examined various parameters, including the composition of the intestinal flora, immune markers such as T-cell activity, and inflammation parameters in the intestinal mucosa.
Further studies examined metabolic parameters such as insulin sensitivity and lipid profiles in individuals with metabolic syndrome. The research also analyzed parameters such as fecal genotoxicity and apoptosis rates in intestinal epithelial cells, as well as microbial diversity in the intestine. Most studies were conducted over a period of at least 3 to 6 weeks.
ABOUT THE RAW MATERIALS
The Lactobacillus strains we have selected are used in microencapsulated form. L. acidophilus LA85 has a live cell count of at least 100 billion CFU per gram; the actual measured concentration is 140 billion CFU/g. L. rhamnosus LRa05 has 150 billion CFU/g. Microencapsulation is a technology that protects live bacteria during gastrointestinal passage. The ASPRIVA CORE formulation contains approximately 10 billion CFU of each strain per daily dose in combination with 3g of inulin, a dosage that has been studied in scientific studies. Both raw materials undergo quality controls and meet purity standards. The single-serving sachets hermetically protect each portion from moisture, oxygen, and light until opened. Unlike cans with measuring spoons, where the contents are exposed to environmental influences each time they are removed, the sachet packaging preserves the stability of the live cell count throughout the shelf life.
